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Summary:  2-year overall survival in 68 trial arms was best described by a model that 
accounted for classical radiobiological factors, chemotherapy effects and survival-limiting 
toxicity. The fitted / ratio was 4.0 Gy and repopulation negated 0.38 Gy/day. Modelled 
survival peaked at 80 (stage IIIA) and 87 Gy (IIIB) for radiotherapy and sequential 
chemoradiotherapy delivered in 2 Gy fractions over 40 days, and 67 (IIIA) and 73 Gy (IIIB) 
for concurrent chemoradiotherapy, before falling at higher doses. 
 
 





Purpose. To analyze changes in 2-year overall survival (OS2yr) with radiotherapy (RT) 
dose, dose-per-fraction, treatment duration and chemotherapy use, in data compiled from 
prospective trials of RT and chemo-RT (CRT) for locally-advanced non-small cell lung 
cancer (LA-NSCLC). 
Material and methods.  OS2yr data was analyzed for 6957 patients treated on 68 trial arms 
(21 RT-only, 27 sequential CRT, 20 concurrent CRT) delivering doses-per-fraction 4.0 
Gy. An initial model considering dose, dose-per-fraction and RT duration was fitted using 
maximum-likelihood techniques. Model extensions describing chemotherapy effects and 
survival-limiting toxicity at high doses were assessed using likelihood-ratio testing, the 
Akaike Information Criterion (AIC) and cross-validation. 
Results. A model including chemotherapy effects and survival-limiting toxicity described 
the data significantly better than simpler models (p <10-14), and had better AIC and cross-
validation scores. The fitted / ratio for LA-NSCLC was 4.0 Gy (95%CI: 2.8-6.0 Gy), 
repopulation negated 0.38 (95%CI: 0.31-0.47) Gy EQD2/day beyond day 12 of RT, and 
concurrent CRT increased the effective tumor EQD2 by 23% (95%CI: 16-31%). For 
schedules delivered in 2 Gy fractions over 40 days, maximum modelled OS2yr for RT was 
52% and 38% for stages IIIA and IIIB NSCLC respectively, rising to 59% and 42% for 
CRT. These survival rates required 80 and 87 Gy (RT or sequential CRT) and 67 and 73 
Gy (concurrent CRT). Modelled OS2yr rates fell at higher doses. 
Conclusions. Fitted dose-response curves indicate that gains of ~10% in OS2yr can be 
made by escalating RT and sequential CRT beyond 64 Gy, with smaller gains for 
concurrent CRT. Schedule acceleration achieved via hypofractionation potentially offers a 




according to the model fit, if critical normal structures in which survival-limiting toxicities 





Overall survival (OS) following radiotherapy (RT) for locally-advanced non-small cell lung 
cancer (LA-NSCLC) remains disappointing. While some dose-escalation trials have 
achieved promising results, [1] outcomes have been inconsistent, with median OS in better 
performing studies being 25-28 months. [2,3] Surprisingly, the RTOG-0617 phase III study 
of concurrent chemoradiotherapy (CRT) found a sub-unity median survival ratio (MSR) of 
0.71 for 74 Gy in 37 daily fractions versus 60 Gy in 30 fractions. [2] Although 
hyperfractionated and moderately hypofractionated schedules have been trialled, [1,3-6] 
the standard-of-care remains 60-66 Gy in 30-33 fractions with some UK centres preferring 
55 Gy in 20 fractions. Improved survival has recently been demonstrated using radio-
immunotherapy [7] but the optimal RT schedule has yet to be determined.  
A need therefore exists to reconcile apparently inconsistent trial results, to improve 
outcome prediction for modified RT of NSCLC. Partridge et al analyzed 2-year disease-
free survival (DFS), demonstrating a dose-response using a probit tumour control 
probability (TCP) model. [8] Differences in dose-per-fraction and schedule duration were 
accounted for by standardizing to equivalent doses in 2 Gy fractions delivered over a fixed 
treatment duration (EQD2T), using the time-corrected linear-quadratic formalism. Values 
of /,  and TK parameters describing fractionation sensitivity, accelerated tumor 
proliferation and onset delay are not well established for NSCLC, [9-12], and therefore 
Partridge et al chose 10 Gy, 0.6 Gy/day and 21 days, similar to values obtained from 
analyses of outcomes for head-and-neck squamous cell carcinoma (HNSCC). [13] 
A recent meta-analysis of randomized studies reported an MSR of 1.13 (p=0.002) for 
higher radiation dose arms in RT-only and sequential CRT trials, but 0.83 (p = 0.02) for 




models to describe differential chemotherapy effects and possible reductions in survival at 
high radiation doses. Here, we analyze 2-year OS rates (OS2yr) compiled for ~7000 
NSCLC patients from published phase I-III trials of RT alone and CRT. Starting from the 
Partridge model, we freely fit /,  and Tk before parsimoniously extending the model to 
describe sequential and concurrent chemotherapy effects, and survival reductions at high 
doses due to radiation toxicity. [14]  
2. Materials and methods 
2.1. Data 
Phase I-III trial data were identified from PubMed, ScienceDirect and Google Scholar 
searches for the MeSH term ‘NSCLC radiotherapy dose-escalation’. Citation-following 
yielded further data. The dataset was limited to studies published after 1995 describing 
outcomes for >20 patients per trial arm. Reports missing unambiguous details of dose, 
fractionation, treatment duration, chemotherapy scheduling, stage-mix and OS2yr data 
were excluded. Strongly hypofractionated schedules used to treat predominantly early-
stage disease (dose-per-fraction >4.0 Gy) were also excluded, substantially weighting the 
dataset towards higher-stage disease. 
Reported prescribed doses and doses-per-fraction were increased by 5% for North 
American trials not employing lung tissue heterogeneity corrections. [15] Doses prescribed 
in the RTOG-0617 study were also raised by 5% despite heterogeneity corrections having 
been applied, since prescription was to 95% of the planning target volume, generating 
physical isocentre doses similar to those of isocentrically-prescribed treatments planned 
without heterogeneity corrections. [16] 




Three models have been fitted to OS2yr data. The first accounts for dose, dose-per-fraction 
and schedule duration. The second contains two additional parameters describing 
systemic and local chemotherapy effects. The third contains two further parameters 
describing survival reductions at high doses, and one accounting for improvements in 
survival over time. 
Model 1: Standard probit-EQD2 
Model 1, based on that of Partridge et al, [8] describes TCP varying sigmoidally with 
EQD2T delivered to the tumor, EQD2Ttum  
   TCP  =   Φ [
EQD2Ttum − EQD2Ttum,50
𝑚. EQD2Ttum,50
]  ×   100%                        (1) 
where  is the cumulative normal distribution, EQD2Ttum,50 is the tumor EQD2T required for 
50% control, and m defines the dose-response gradient. EQD2Ttum was calculated as 
  EQD2Ttum  =   𝐷 [(1 + (
𝑑
 𝛼 𝛽 𝑡𝑢𝑚⁄
)) (1 + (
2
 𝛼 𝛽 𝑡𝑢𝑚⁄
))⁄ ]  −   𝜆. Max[𝑇 − 𝑇𝑘, 0]              (2) 
D and d being prescribed dose and dose-per-fraction, and T treatment duration. [8] 
Following Partridge’s approach, cohort-specific OS was calculated as a weighted sum of 
modelled TCPs for each disease stage 
  OS2yr
Model1  =   100% × ∑ 𝑓𝑖𝑖  ×  Φ [
EQD2Ttum − EQD2Ttum,50(𝑆𝑖)
𝑚. EQD2Ttum,50(𝑆𝑖)
]                 (3) 
where fi is the fraction of patients in the cohort with stage i (I, II, IIIA or IIIB) disease, 
and EQD2Ttum,50(𝑆𝑖) the EQD2Ttum,50 for that stage. Initially, /tum,  and Tk values were 




EQD2Ttum,50(𝑆I, II, IIIA, IIIB) were fitted to achieve the best description of the data (‘Partridge 
model’). Subsequently all eight model parameters were fitted (‘Model 1’). 
2.2.1. Model 2: Adding chemotherapy effects 
Survival is improved by chemotherapy-driven reductions in the distant failure-rate. [17,18]. 
Model 2 describes this effect via an additional factor  
   OS2yr
Model2   =   (
OS2yr−max
100%
  )  OS2yr
Model1                (4) 
where OS2yr-max values <100% account for patients who died of distant metastases or 
unrelated causes despite achieving loco-regional control. For RT alone, OS2yr-max
RT-only
 was 
fixed at 85%, based on a reported distant failure-rate of 15% post-surgery for patients who 
did not receive chemotherapy. [19] For CRT treatments, OS2yr-max
CRT
 was fitted to obtain the 
best match of the model to the data, a value >85% describing reduced distant failure-
related mortality due to systemic effects of chemotherapy.   
Survival is longer following concurrent than sequential CRT. [20, 21] This is accounted for 
by scaling the EQD2Ttum doses of concurrent CRT treatments by an additional fitted 
parameter RScCRT >1 to describe possible tumor radiosensitization by concurrent 
chemotherapy  
   EQD2Ttum
cCRT   =   RScCRT .  EQD2Ttum                (5) 
Model 2 has ten fitted parameters. Its residuals revealed an unfitted trend for OS2yr to rise 
with study publication year (see Supplementary Information), presumably reflecting 
advances in treatment and staging over time unrelated to CRT scheduling, and concurring 
with a reported trend for significantly longer survival in more recent studies [6]. Survival 
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Model2b  =   OS24m
Model2  (1 − 𝑅. 𝑌)              (6) 
Y being the number of years before 2016 a study was published, and R a fitted parameter 
describing survival benefit with time.  
2.2.2. Model 3: Reduced survival at higher doses 
Model 2 cannot describe falling survival at high doses. However, the concept of a 
therapeutic window implies that OS must rise, plateau and eventually fall as RT dose 
increases. To accommodate this, we extended the model to 
   OS2yr
Model3  =  OS2yr
Model2b  (1 −
𝑆𝐿𝑇
100%
)                 (7) 
where the modelled survival-limiting toxicity-rate, SLT, is given by 
   𝑆𝐿𝑇  =   Φ [
EQD2NT − EQD2NT,50
𝑚NT. EQD2NT,50
]  ×  100%                        (8) 
and increases sigmoidally with the normal tissue EQD2 
    EQD2NT = 𝐷 [(1 + (
𝑑
3
)) (1 + (
2
3
))⁄ ]                     (9) 
calculated using / = 3 Gy. The fitted quantities mNT and EQD250,NT define the toxicity 
dose-response gradient and the EQD2NT at which survival is halved by toxicity, and bring 
the number of fitted parameters in Model 3 to 13. 
2.3. Statistical methods 
Models were fitted to OS2yr data using the maximum-likelihood method, via the mle2 
package within the ‘R’ language (v3.4.0). [22] Significances of improvements in model-fit 
were determined using likelihood-ratio testing. [23] Relative model performance in future 




goodness-of-fit against a penalty term that rises with the number of fitted parameters to 
account for possible overfitting of the dataset. [24] Leave-one-out cross-validation was 
performed to check the AIC findings, calculating weighted sums-of-squared residuals. 
For each model, asymptotic confidence intervals (CIs) were calculated on all fitted 
parameters. For the model judged best on AIC and cross-validation, profile-likelihood CIs 
were also determined. [22] 
3. Results 
3.1. Data 
The dataset comprised 6957 patients treated on 68 trial arms of 40 studies, for which 2-
year OS ranged from 6 to 68%. [1-5,25-64] Overall, 9% of patients were stage I, 9% stage 
II, 43% IIIA and 39% IIIB (AJCC 6th edition). RT alone, sequential and concurrent CRT 
treatments were given in 21, 27 and 20 arms respectively (Table 1).  
Figure 1a shows observed OS2yr plotted against prescribed physical dose. Although the 
data appear highly dispersed, local regression (LOESS, smoothing = 0.7) shows survival 
increasing with dose before plateauing at ~80 Gy. Physical dose and dose-per fraction are 
plotted against RT duration in Figure 1b and Supplementary Figure S1. Higher doses were 
typically given using longer schedules (Spearman’s rho = 0.62, p <0.001), but dose-per-
fraction and schedule duration were not significantly correlated (p = 0.66). 
3.2. Data fits 
Model fits to 2-year survival data are detailed in Table 2. The data were described 
significantly better when classical radiobiological parameters /,  and TK were fitted 
rather than fixed at the levels of the Partridge model (p<10-5). The fit was further improved 




studies (p<10-8, Supplementary Table S1 and Figure S2), and reduced survival at high 
dose-levels (p<10-6). Model 3 included all these factors and described the data best 
(Figure 2). 
Values of OS2yr predicted by Model 3 are plotted in Figure 3a and rise with observed OS2yr, 
with notably less data dispersion than in Figure 1. A plot of predicted and observed OS2yr 
versus EQD2Ttum shows no trend in residuals (Figure 3b). On AIC and cross-validation 
measures Model 3 substantially out-performed the other models (Table 2), indicating that 
its success was not due to over-fitting of this specific dataset.    
The fitted / ratio was 4.0 Gy (profile-likelihood 95% CI: 3.0, 5.4 Gy) for Model 3, with a 
tumor repopulation rate  of 0.38 Gy/day (95%CI: 0.30, 0.48 Gy/day) beginning at day 12 
[95%CI: 12, 17] of RT. Relatively low / ratios were common to fits of Models 1, 2 and 3. 
For Model 2b a higher / value of 7.4 Gy (95%CI: 2.7, 12.4 Gy) was obtained, but Model 
3 described the dataset substantially better. In fits of Models 1 and 2, tumor repopulation 
ran faster at 0.71 and 0.97 Gy/day starting at day 28, but again Model 3 described the data 
significantly better. The Model 3 fit described a maximum dose-response gradient of 
1.25% (95% CI: 1.13, 1.42%) gain in OS2yr per 1% increase in EQD2Ttum, in the absence 
of survival-limiting toxicity. 
3.3. Dose-response curves 
Dose-response curves for OS2yr described by Model 3 are plotted in Figure 4 for RT alone, 
sequential and concurrent CRT. For ease of comparison with a reference schedule 
delivering 60 Gy in 30 fractions over 6 weeks (40 days), OS2yr is plotted against dose 
delivered in 2 Gy fractions over 40 days, EQD2(40d)tum, where 




The plots show predicted OS2yr peaking at 52% and 38% respectively for stages IIIA and 
IIIB NSCLC treated using RT alone, and at 59% and 42% for CRT treatments. For RT 
alone and sequential CRT, peak survival is reached at EQD2(40d)tum doses of 80 and 87 
Gy for stages IIIA and IIIB respectively. For concurrent CRT, peak survival requires 67 and 
73 Gy for IIIA and IIIB disease. Some of these dose-levels, 87 Gy for example, would 
exceed tolerance for serious toxicities [8]. At higher dose-levels the model fit describes 
falling survival, gains in tumor control being more than offset by survival-limiting toxicity.    
Discussion 
NSCLC OS2yr data was described best by Model 3 (Table 2, Figure 2), which includes 
terms accounting for sequential and concurrent CRT, and toxicity-related reductions in 
survival at high doses. Although survival is known to be improved by CRT, [20] and is 
suspected to be limited by toxicity at high doses, [14, 65] to our knowledge this is the first 
time these factors have been included in comprehensive dose-response modelling for 
NSCLC. 
The 4.0 Gy (95%CI: 3.0, 5.4 Gy) / ratio of the Model 3 fit is notably lower than the 10 Gy 
value often assumed for NSCLC [10], and allowed the model to describe the data 
significantly better (p <.002, likelihood-ratio). A similar value of 4.9 Gy (95%CI: 3.0, 6.8 Gy) 
was obtained when the radiobiological parameters of the standard Partridge model were 
freely-fitted (Model 1, Table 2), indicating that the result is robust and not an artefact of 
modelling CRT and toxicity-limited survival. We are unaware of such a low / ratio being 
previously reported for LA-NSCLC, but the 4.0 Gy / value is consistent with an 
observation of Partridge et al. [8]  that hypofractionated schedules appeared to over-
perform in plots of DFS versus EQD2Ttum calculated for / = 10 Gy, and concurs with / 




Tumor repopulation negates 0.38 Gy EQD2 per day of treatment extension beyond day 12 
of RT according to the Model 3 fit, making RT acceleration worth ~3 Gy per week of 
schedule shortening. Since the fitted tumour / value of 4.0 Gy lies close to the generic 
late toxicity / ratio of 3 Gy, such acceleration might be achieved efficiently via moderate 
hypofractionation (dose-per-fraction >2 Gy) including simultaneous boost techniques. For 
example, 56 Gy in 20 fractions over 26 days offers a modelled 5% advantage in OS2yr for 
stage IIIB NSCLC compared to 63 Gy in 30 fractions over 40 days, the two schedules 
being equivalent for late normal tissue damage (/ = 3 Gy). 
The fitted 0.38 Gy/day loss of EQD2 to repopulation is similar to an early estimate of 0.45 
Gy/day made for NSCLC by Koukourakis et al [68], but is lower than estimates for HNSCC 
(~0.6 Gy/day starting 3-5 weeks into RT [13]), and depends strongly on the introduction of 
the toxicity term into Model 3. Fits of the simpler but less well-performing Models 1, 2 and 
2b described higher loss-rates of 0.6-1.0 Gy/day typically starting at day 28 of RT, a 
consequence of these models using rapid repopulation rather than survival-limiting toxicity 
to fit the observed plateau in OS2yr at high doses, albeit less well.  
The systemic effect of chemotherapy compared to RT alone was described in the Model 3 
fit by a 10% rise in OS2yr-max, the overall survival achievable by a treatment if 100% of 
primary tumours were cured and no survival-limiting toxicity occurred. And the local effect 
of concurrent chemotherapy was described by a modelled 23% increase in effective tumor 
EQD2, greater than estimated previously [9] but consistent with the 0.86 hazard ratio 
reported by O’Rourke et al for concurrent rather than sequential CRT [20]. 
The model fit was significantly improved by the toxicity term, which was introduced to 
account for survival reductions at high dose-levels, and described survival-limiting toxicity 




sequential CRT, and 8%, 23% and 42% following concurrent CRT. These modelled rates 
suggest that survival in dose-escalation trials may have been reduced by toxicity, and are 
in line with data from a cause-of-death analysis [69], which reported an ~15% rate of non-
malignant cardiac mortality at 2 years post-treatment for a curatively treated stage III 
cohort. Research is being carried out to identify mediastinal substructures in which 
survival-limiting toxicities arise, with a focus on heart [14], offering the prospect of 
improved outcomes if doses to these structures can be limited without compromising 
tumor coverage. 
Whilst Model 3 was designed to parsimoniously account for several classical and novel 
dose-response factors, it nevertheless requires fitting of 13 parameters. This relative 
complexity is justified by the model’s superior AIC and cross-validation scores, compared 
to those of simpler models. Further terms might provide a more complete description of the 
dataset, or might simply overfit it. We have investigated stage-specific survival-limiting 
toxicity terms, motivated by the observation that critical structures are less likely to receive 
high doses during RT of early-stage disease: resulting improvements in AIC score were 
marginal (Supplementary Information). 
In summary, we have fitted a dataset of OS2yr rates reported for many RT and CRT 
schedules using a model that combined a classical description of radiation dose-response 
with novel terms accounting for chemotherapy effects and survival reductions at high 
doses. The model fit had an / ratio of 4.0 Gy and described a rate of EQD2 loss due to 
tumor repopulation of 0.38 Gy/day, implying that moderate acceleration achieved via 
hypofractionation would produce useful survival gains. 
The fit predicts maximal OS2yr rates of 52% (stage IIIA) and 38% (IIIB) for RT alone when 




rates being achieved at prescribed doses of 80 Gy (IIIA) and 87 Gy (IIIB) for RT alone and 
sequential CRT, and 67 Gy (IIIA) and 73 Gy (IIIB) for concurrent CRT. According to the fit, 
10-20% further improvements in OS2yr might be achieved if normal tissues in which 
survival-limiting toxicities arise could be identified and spared without compromising tumor 
dose coverage. 
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Table 1. Dataset details. ‘Accelerated’ achedules delivered >1 fraction-per-day; ‘hyperfractionated’ 
and ‘hypofractionated’ schedules gave doses-per-fraction of 1.6 and 3.0 Gy respectively. 
Accelerated and hyperfractionated categories overlap.  
*1174 patients were split 50/50% stage I versus II; the split for a further 37 patients was not published and 50/50% was 
assumed.  
**5682 patients were split 52/48% stage IIIA vs IIIB, with a 50/50 split assumed for the other 64 patients. 




 68 trial arms, 6957 patients 













Stage I/II = 397 
Stage IIIA/IIIB = 1174 
Sequential CRT: 27 
Accelerated: 4 
Hyperfractionated: 1 
Hypofractionated: 0  
 
3023 
Stage I/II = 720 
Stage IIIA/IIIB = 2303 






Stage I/II = 94 
Stage IIIA/IIIB = 2269 
 Mean  Range Mean Range Mean Range 
Dose† (Gy) 64.7  40.0-81.0 70.8 55.0-96.6 67.3 55.0-77.7 
Dose-per-
fraction  (Gy) 
2.10  1.26-4.00 2.10 1.68-2.75 2.02 1.26-2.75 
Number of 
fractions  
33.1  10-58 33.8 20-46 35.2 20-58 
RT duration 
(days) 
35.3  12-55 43.0 16-64 41.4 21-52 










CRT effects added 
 
Model 3 
CRT, publication date and toxicity effects added 
Fit, DoF= 63 Fit, DoF= 60 Fit, DoF = 58  Fit, DoF = 55  
(asymptotic 95% CI) (asymptotic 95% CI) (asymptotic 95% CI)  (profile-likelihood 95% CI) (asymptotic 95% CI) 
 Fitted parameters 
 
 tum Gy 10† 4.9 (3.0, 6.8) 4.2 (2.1, 6.2)  4.0 (3.0, 5.4) (2.3, 5.6) 
 Gy/day 0.6† 0.71 (0.58, 0.83) 0.97 (0.72, 1.21)  0.38 (0.30, 0.48) (0.26, 0.51) 
Tk Days 21† 28 (27, 29) 28 (27, 29)  12 (12*, 17) (10, 14) 
EQD2Ttum,50(SIIIa) Gy 69 (63, 74) 69 (63, 74) 75 (66, 84)  51 (45, 57) (44, 59) 
 EQD2Ttum,50(SI) Gy -12 (-22, -3) -11 (-19, -4) -33 (-45, -22)  -11 (-21, -6) (-20, -2) 
 EQD2Ttum,50(SII) Gy 38 (9, 77) 49 (13, 85) 17 (-13, 47)  -4.2 (-11.3, 2.4) (-13.6, 5.1) 
 EQD2Ttum,50(SIIIb) Gy 9 (-1, 16) 8 (-2, 18) 13 (-5, 31)  13.2 (4.6, 20.4) (1.3, 25.2) 
m - 0.62 (0.51, 0.73) 0.66 (0.57, 0.75) 0.82 (0.65, 1.00)  0.39 (0.25, 0.55) (0.15, 0.62) 
OS24m-max
Ch-RT  % - - 96 (89, 103)  95 (89, 103) (86, 104) 
RSConc-Ch-RT - - - 1.29 (1.19, 1.39)  1.23 (1.16, 1.31) (1.12, 1.34) 
R per year - - -  0.018 (0.013, 0.020) (0.014, 0.024) 
EQD2NT,50 Gy - - -  105 (97, 116) (94, 115) 
mNT - - - -  0.30 (0.15, 0.80) (-0.08, 0.69) 
 Fixed parameters 
OS24m-max
RT-only
 %  - 85  85  
 NT Gy  - -  3  
 Fit quality measures 
AIC  9147.2 9136.0 9050.4  8985.0  
Cross-validation score  439.1 423.7 363.5  215.1  
Likelihood-ratio p value**  - 5x10-6 3x10-20  2x10-15  
† Parameters fixed at values derived from HNSCC by Partridge et.al. * For TK the profile-likelihood 95% confidence interval lower limit is fixed at 12 days.  **Significance of the 




Figure 1. a) Observed OS2yr vs. prescribed physical dose for the analyzed trial arms. LOESS 
regression (solid line) indicates dose-response in the region 40-80 Gy. b) Physical dose vs. RT 
schedule duration (RT only - open, sequential chemo-RT - striped, concurrent CRT - closed; larger 





Figure 2. Calibration plots of predicted versus observed OS2yr across the dataset, for fits of Models 
1-3. Patients per trial arm are represented by areas of plotted points. Weighted least-square fits to 
the data (solid lines) are shown along with the line-of-identity. The gradients of the plots increase 







Figure 3. a) Observed (closed) and predicted (open) OS2yr rates plotted against EQD2Ttum.  b) 
Residuals (grey). Symbol sizes reflect patient numbers per trial arm. 




Figure 4. (a-c) OS2yr dose-response curves calculated from the Model 3 fit for (a) RT alone, (b) 
sequential CRT, (c) concurrent CRT. Curves for stage I, II, IIIA and IIIB NSCLC are plotted as 
dashed grey, dashed black, solid grey and solid black lines. The peaks of the IIIA curves are 
picked out. (d) Schematic showing composition of OS as a product of survival unlimited by toxicity 









Study of stage-specific survival limiting toxicity rates 
Goodness-of-fit measures (likelihood-ratio, AIC, leave-one-out cross validation) all indicated that 
Model 3 was preferred over simpler models despite its relative complexity. Here we explore 
whether a more complex model might further improve the data description. 
Early-stage NSCLC tumors are smaller with less mediastinal involvement, and thus critical normal 
structures in patients with early-stage disease are potentially less likely to receive prescription-level 
doses, reducing rates of survival-limiting toxicity in these patients.   
We therefore tested a variant of Model 3 in which the fraction f(SI) of patients with stage I disease 
who might possibly experience survival-limiting toxicity (because critical structures received the 
prescribed dose) was freely fitted rather than being assumed to be 100%. The fitted value of f(SI) 
was 51%, and while the model was preferred on AIC and cross-validation to Model 3, the 
difference was marginal (Table S2). When the fraction was freely fitted for all stages (rather than 
just for stage I and being fixed at 100% for the rest) the resulting model was disfavoured on AIC 
and cross-validation, indicating a risk of overfitting. Overall, therefore, in the main part of the study 





Table S1. Degrees of freedom (DoF), parameter values and 95% confidence intervals for the 




CRT and publication date 
effects added 
Fit, DoF = 57 
(asymptotic 95% CI) 
  Fitted Parameters 
 tum Gy 7.5 (2.7,  12.4) 
 Gy/day 0.59 (0.42, 0.77) 
Tk Days 12 (10, 14) 
EQD2Ttum,50(SIIIa) Gy 54 (45, 62) 
 EQD2Ttum,50(SI) Gy -25 (-34, -16) 
 EQD2Ttum,50(SII) Gy 3 (-14, 20) 
 EQD2Ttum,50(SIIIb) Gy 16 (-8, 32) 
m - 0.94 (0.68, 1.21) 
OS24m-max
Ch-RT
 % 93 (86, 99) 
RSConc-Ch-RT - 1.22 (1.13, 1.30) 
R per year 0.018 (0.015, 0.022) 
EQD2NT,50 Gy - 
mNT - - 
  Fixed Parameters 
OS24m-max
RT-only
 % 85 
 NT Gy - 
  Fit quality measures 
AIC  9012.1 
Cross-validation score  261.1 
Likelihood-ratio p value†  210-9 
 






Table S2. Effect of fitting the fraction f(SI) of stage I patients in whom critical normal structures 
receive the prescribed dose-level and survival-limiting toxicities can occur (set to 100% for all 




CRT, publication date and toxicity effects added 
 Fit, DoF = 55; f(SI) set to 1 Fit, DoF = 54; f(SI) fitted 
 (asymptotic 95% CI) (asymptotic 95% CI) 
   Fitted parameters 
 tum Gy  4.0 (3.0, 5.4) 4.2 (2.2, 6.2) 
 Gy/day  0.38 (0.30, 0.48) 0.38 (0.26, 0.49) 
Tk Days  12 (12*, 17) 12 (10, 14) 
EQD2Ttum,50(SIIIa) Gy  51 (45, 57) 47 (38, 57) 
 EQD2Ttum,50(SI) Gy  -11 (-21, -6) -5.2 (-17.1, 6.7) 
 EQD2Ttum,50(SII) Gy  -4.2 (-11.3, 2.4) -3.6 (-12.0, 4.8) 
 EQD2Ttum,50(SIIIb) Gy  13.2 (4.6, 20.4) 8.9 (1.5, 16.2) 
m -  0.39 (0.25, 0.55) 0.28 (0.15, 0.40) 
OS24m-max
Ch-RT
 %  95 (89, 103) 95 (86, 105) 
RSConc-Ch-RT -  1.23 (1.16, 1.31) 1.19 (1.10, 1.27) 
R per year  0.018 (0.013, 0.020) 0.018 (0.014, 0.025) 
EQD2NT,50 Gy  105 (97, 116) 100 (85, 115) 
mNT -  0.30 (0.15, 0.80) 0.63 (-0.44, 1.70) 
f(SI) -  1 0.51 (-0.02, 1.04) 
   Fixed parameters 
OS24m-max
RT-only
 %  85 85 
 NT Gy  3 3 
   Fit quality measures 
AIC   8985 8984.7 
Cross-validation score   215.1 217.3 
 






Figure S1. Dose-per-fraction plotted against RT duration for the trial arms analyzed. Patient 
numbers-per-trial arm are represented by areas of plotted points. 






Figure S2: Model 2 fit residuals (differences between observed and fitted OS2yr) versus year of 
publication. Symbol sizes reflect patient numbers per trial arm. The solid line is a weighted least 
squares linear fit to the data. 
 
 
 
 
 
